Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Liu

Showing results (361-370 of 420) with videos related to

Pageof 42
Sort By:
Biorxiv : the Preprint Server for Biology|May 7, 2024
Specific oncogene activation of the cell of origin in mucosal melanomaSwathy Babu, Jiajia Chen, Emily Robitschek, et al.
Cancer Discovery|April 2, 2025
Correction: DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional ReprogrammingIlaria Gritti, Jinkai Wan, Vajira Weeresekara, et al.
The Journal of Clinical Psychiatry|February 16, 2017
Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) StudyMadhukar H Trivedi, Tracy L Greer, Chad D Rethorst, et al.
Scientific Reports|July 30, 2024
JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humansAnne M Fourie, Xiaoli Cheng, Leon Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS studyJosep M Llovet, Thomas Decaens, Jean-Luc Raoul, et al.
Cancer Research|June 8, 2021
Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell SurvivalRiaz Gillani, Bo Kyung A Seong, Jett Crowdis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2018
<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder CancerQiang Li, Alexis W Damish, Zoë Frazier, et al.
Nature Communications|July 22, 2025
Specific oncogene activation of the cell of origin in mucosal melanomaSwathy Babu, Jiajia Chen, Chloé S Baron, et al.
JCO Precision Oncology|December 14, 2019
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung CancerNatalie I Vokes, David Liu, Biagio Ricciuti, et al.
Nature Communications|September 1, 2025
Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanomaJiekun Yang, Cassia Wang, Doris Fu, et al.
Pageof 42

Showing results (361-370 of 420) with videos related to

Sort By:
Pageof 42
Biorxiv : the Preprint Server for Biology|May 7, 2024
Specific oncogene activation of the cell of origin in mucosal melanomaSwathy Babu, Jiajia Chen, Emily Robitschek, et al.
Cancer Discovery|April 2, 2025
Correction: DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional ReprogrammingIlaria Gritti, Jinkai Wan, Vajira Weeresekara, et al.
The Journal of Clinical Psychiatry|February 16, 2017
Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) StudyMadhukar H Trivedi, Tracy L Greer, Chad D Rethorst, et al.
Scientific Reports|July 30, 2024
JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humansAnne M Fourie, Xiaoli Cheng, Leon Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS studyJosep M Llovet, Thomas Decaens, Jean-Luc Raoul, et al.
Cancer Research|June 8, 2021
Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell SurvivalRiaz Gillani, Bo Kyung A Seong, Jett Crowdis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2018
<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder CancerQiang Li, Alexis W Damish, Zoë Frazier, et al.
Nature Communications|July 22, 2025
Specific oncogene activation of the cell of origin in mucosal melanomaSwathy Babu, Jiajia Chen, Chloé S Baron, et al.
JCO Precision Oncology|December 14, 2019
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung CancerNatalie I Vokes, David Liu, Biagio Ricciuti, et al.
Nature Communications|September 1, 2025
Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanomaJiekun Yang, Cassia Wang, Doris Fu, et al.
Pageof 42